Merck tees up Prevymis filing in kidney transplant recipients after phase 3 trial win

Since it hit the market in 2017 to prevent cytomegalovirus (CMV) infection in stem cell transplant patients, Merck’s Prevymis has racked up steadily increasing sales.

With results from a phase 3 study—presented Saturday at IDWeek 2022—Merck has a chance to expand the medicine's reach to kidney transplant recipients.